phase readout
saveNCT07181941: Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma
RECRUITINGupdated 2mo ago
community read0 votes
Sponsor: Fred Hutchinson Cancer Center. Phase: PHASE1. Conditions: Recurrent Multiple Myeloma, Refractory Multiple Myeloma
view source ↗
comments(0)
5-min edit window · permanent after that